← Eichor
Study identifier: NCT04545424 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Trial of Therapeutic Hypothermia in Patients With ARDS

Condition: Respiratory Distress Syndrome, Adult  ·  Sponsor: University of Maryland, Baltimore

PhasePhase 2
Planned participants340
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication of TH, often requiring paralysis with neuromuscular blocking agents (NMBA) to control. Since the recently completed NHLBI PETAL ROSE trial showed that NMBA had no effect (good or bad) in patients with moderate to severe ARDS, the CHILL trial is designed to evaluate whether TH combined with NMBA is beneficial in patients with ARDS. This Phase IIb randomized clinical trial is funded by the Department of Defense to compare TH (core temperature 34-35°C) + NMBA for 48h vs. usual temperature management in patients in 14 clinical centers with the Clinical Coordination Center and Data Coordinating Center at University of Maryland Baltimore. Planned enrollment is 340 over \~3.5 years of the 4-year contract. COVID-19 is considered an ARDS risk-factor and patients with ARDS secondary to COVID-19 pneumonia will be eligible for enrollment. Primary outcome is 28-day ventilator-free days. Secondary outcomes include safety, physiologic measures, mortality, hospital and ICU length of stay, and serum b…

This description comes directly from the study's public registry record.

Talk to the study team

Carl B Shanholtz, MD  ·  410-328-8141  ·  cshanhol@som.umaryland.edu

Michael L Terrin, MD/MPH  ·  410-706-6139  ·  mterrin@som.umaryland.edu

Always discuss trial participation with your own doctor first.

Locations (19)

Cedars-Sinai Medical CenterLos Angeles, California, United StatesNot Yet Recruiting
Yale UniversityNew Haven, Connecticut, United StatesTerminated
Emory UniversityAtlanta, Georgia, United StatesRecruiting
Rush University Medical CenterChicago, Illinois, United StatesRecruiting
Loyola University ChicagoChicago, Illinois, United StatesTerminated
University of KentuckyLexington, Kentucky, United StatesNot Yet Recruiting
University of Maryland Medical CenterBaltimore, Maryland, United StatesRecruiting
Johns Hopkins HospitalBaltimore, Maryland, United StatesTerminated
Henry Ford HospitalDetroit, Michigan, United StatesRecruiting
Cooper Health SystemCamden, New Jersey, United StatesRecruiting
University of CincinnatiCincinnati, Ohio, United StatesRecruiting
Cleveland ClincCleveland, Ohio, United StatesRecruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04545424